Tag Archives: First

AstraZeneca, Merck's Lynparza posts pancreatic cancer win in another PARP-class first

AstraZeneca and Merck’s Lynparza has already led its class into two disease areas, and now it’s looking to make it three. Tuesday, the companies said their PARP inhibitor had topped placebo at staving off progression of tough-to-treat pancreatic cancer in patients with germline BRCA-mutated forms of the disease. The phase 3 study, dubbed POLO, examined Lynparza in… Read More »

FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Print this page HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the most common form of leukemia in adults.1 This is… Read More »